Axcelis Tech Ord Stock Price, News & Analysis

Axcelis Technologies (NASDAQ: ACLS) reported Q1 2025 financial results with revenue of $192.6 million, showing a decline from $252.4 million in Q1 2024. The company maintained strong margins with a GAAP gross margin of 46.1% and non-GAAP gross margin of 46.4%. Net income decreased to $28.6 million ($0.88 per diluted share) from $51.6 million ($1.57 per diluted share) year-over-year. For Q2 2025, Axcelis projects revenue of approximately $185 million with GAAP EPS of $0.57 and non-GAAP EPS of $0.73, indicating continued market challenges. Despite the revenue decline, the company maintains a strong financial position with no debt and continues share repurchases while investing in innovation.

Axcelis Technologies (NASDAQ: ACLS) announced its sponsorship and participation in the Advanced Semiconductor Manufacturing Conference (ASMC) scheduled for May 5-8, 2025, in Albany, New York. The company will present research on particle control for low-energy boron implantation in Session 5: Contamination Free Manufacturing.

Dr. Phillip Geissbuhler, Staff Scientist at Axcelis, will present findings from a collaborative study with SK Hynix on May 6, 2025. The presentation focuses on new hardware implementation that reduces particle contamination during low-energy boron implants by increasing ion beam angles to enhance self-sputtering of films. This innovation significantly reduces film buildup on surfaces near implanted wafers, addressing a critical yield-impacting issue in semiconductor manufacturing.

Axcelis Technologies (NASDAQ: ACLS) has issued a correction to their previous press release regarding their participation in the Advanced Semiconductor Manufacturing Conference (ASMC). The correction pertains to two coauthor names: Charlie Free (previously listed as David Free) and DaeYoon Kim (previously listed as Dae Yun Kim).

The company will sponsor ASMC, scheduled for May 5-8, 2025, at the Hilton Albany, New York. During Session 5: Contamination Free Manufacturing on May 6, Dr. Phillip Geissbuhler will present research on 'Particle Control for Low-Energy Boron Implantation' at 3:40 PM.

The presentation details a case study on reducing particle contamination during low-energy boron implants through new hardware implementation. The innovation increases ion beam angle to enhance self-sputtering of films, significantly reducing film buildup on surfaces near implanted wafers, thereby improving device yields.

Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results before market opening on Tuesday, May 6, 2025, followed by a conference call at 8:30 a.m. ET the same day.

Investors can access the earnings call via webcast through Axcelis' website investor section or by registering directly as participants. The webcast replay will remain available for 30 days after the call.

Axcelis Technologies (Nasdaq: ACLS) announced its participation as the Diamond Sponsor for the Compound Semiconductor Asia Conference (CS Asia) 2025, held alongside SEMICON China 2025 from March 25-27, 2025, at the Kerry Hotel in Pudong, Shanghai.

The company's President and CEO, Russell Low, will deliver a keynote speech titled 'Innovation in Ion Implantation for Power and Compound Semiconductor Devices' at 14:30 in Shanghai Ballroom 3. As a leading supplier of ion implantation solutions for the semiconductor industry, Axcelis aims to showcase its broad portfolio and technical expertise to Chinese chipmakers.

Axcelis Technologies (ACLS) has announced a significant expansion of its share repurchase program, with its Board of Directors approving an additional $100 million in share repurchase authorization. This increase brings the total outstanding repurchase authorization to $215 million.

The company plans to increase its quarterly share repurchase activity while maintaining a strong balance sheet. The repurchases may be executed through open market or privately negotiated transactions under SEC's Rule 10b-18, with the possibility of implementing Rule 10b5-1 trading plans. President and CEO Russell Low attributed this decision to the company's strong cash position and solid execution, expressing confidence in their long-term business fundamentals.

The program remains flexible, as Axcelis has no obligation to repurchase shares and may suspend or discontinue the program at any time, subject to market conditions and other factors.

Axcelis Technologies (Nasdaq: ACLS), a leading ion implantation solutions provider for the semiconductor industry, has announced its participation in two major upcoming investor conferences.

The company will attend the Susquehanna Financial Group Fourteenth Annual Technology Conference at the Lotte New York Palace Hotel on February 27-28, 2025, where management will conduct one-on-one and small group meetings with investors on February 27th.

Additionally, Axcelis will participate in the Morgan Stanley Technology, Media & Telecom Conference at the Palace Hotel, San Francisco, from March 3-6, 2025, with management hosting investor meetings on March 4th. Interested investors can arrange meetings through respective conference representatives.

Axcelis Technologies (NASDAQ: ACLS) reported Q4 2024 financial results with revenue of $252.4 million and diluted EPS of $1.54. The company's full-year 2024 performance showed revenue of $1.02 billion, down from $1.13 billion in 2023. Systems revenue decreased to $782.6 million from $883.6 million in 2023.

Despite revenue decline, gross margin improved to 44.7% in 2024 from 43.5% in 2023. Net income for 2024 was $201 million with diluted EPS of $6.15, compared to $246.3 million and $7.43 EPS in 2023. For Q1 2025, Axcelis expects revenues of approximately $185 million and diluted EPS of $0.38.

Management anticipates a near-term cyclical digestion period as customers absorb mature node capacity investments, particularly in China. The company plans to focus on product innovation, cost management, and customer collaboration to position for future growth.

Axcelis Technologies (NASDAQ: ACLS) announced its participation in SEMICON Korea 2025, scheduled for February 19-21 at the COEX Center in Seoul. The company will showcase its Purion™ platform of ion implanters at Booth #D622.

The exhibition will feature the company's flagship Purion™ Platform, offering advanced ion implantation technology for various applications, and the Purion Power Series™, designed for power devices with multi-wafer size compatibility. Axcelis will also display new upgrade offerings, including innovative source technology and productivity packages.

CEO Russell Low emphasized Korea's importance as a market and highlighted the company's expanded operations through its recently opened Asia HUB Warehouse and Axcelis Asia Operations Center, enhancing their manufacturing, engineering, services, and logistics capabilities in the Asia Pacific region.